**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Emily B. Martin
University of Tennessee Graduate School of Medicine
Knoxville, TN

**Main Body of the Abstract**
Background: Iodine-124-evuzamitide, is a novel radiotracer for the detection of systemic amyloidosis by PET/CT imaging, which is an inherently quantitative modality. Therefore, this technique can be used to monitor progression and regression of organ-specific amyloid load. Here we report a single site, open-label, repeat imaging study (NCT05968846) of nine AL (n=9) and ten ATTR (n=10) patients imaged 2.9±0.9 years apart.  Changes in organ-specific radiotracer uptake were quantified and analyzed.
Methods:  Patients received 1 or 2 mCi 124I-evuzamitide with PET/CT imaging at 5 h post injection. A manual 2D region of interest (ROI) analysis of the heart was performed and standard uptake value ratios (SUVRmean) calculated. Contemporaneous serum biomarkers including NTproBNP were collected at each imaging session. Correlation analyses were used to test for associations between variables.
Results: All patients with ATTR (n=10) received stabilizer or silencer therapy between imaging, whereas seven of the nine (7/9) AL patients were untreated during this time. In the whole population (N=19), there was a significant correlation between the change in cardiac SUVRmean (%) and the change in serum NTproBNP (%) (rS=0.57, p=0.011). Eight (n=8; 89%) AL patients and seven (n=7, 70%) ATTR patients had a decrease in cardiac SUVR. Cardiac uptake of 124I-evuzamitide (N=19) correlated significantly with contemporaneous serum NTproBNP (rP=0.64, p=0.0034).
Conclusion:  124I-evuzamitide uptake in the heart may be used to monitor changes in amyloid load (Fig. 1). These pilot data indicate that changes in radiotracer uptake correlate with changes in serum NTproBNP, a validated biomarker predictive of survival in AL amyloidosis.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Emily B. Martin
University of Tennessee Graduate School of Medicine
Knoxville, TN

**Main Body of the Abstract**
**Background:** Iodine-124-evuzamitide, is a novel radiotracer for the detection of systemic amyloidosis by PET/CT imaging, which is an inherently quantitative modality. Therefore, this technique can be used to monitor progression and regression of organ-specific amyloid load. Here we report a single site, open-label, repeat imaging study (NCT05968846) of nine AL (_n_=9) and ten ATTR (_n_=10) patients imaged 2.9±0.9 years apart.  Changes in organ-specific radiotracer uptake were quantified and analyzed.
**Methods:**  Patients received 1 or 2 mCi ^124^I-evuzamitide with PET/CT imaging at 5 h post injection. A manual 2D region of interest (ROI) analysis of the heart was performed and standard uptake value ratios (SUVRmean) calculated. Contemporaneous serum biomarkers including NTproBNP were collected at each imaging session. Correlation analyses were used to test for associations between variables.
**Results**: All patients with ATTR (_n_=10) received stabilizer or silencer therapy between imaging, whereas seven of the nine (7/9) AL patients were untreated during this time. In the whole population (_N_=19), there was a significant correlation between the change in cardiac SUVRmean (%) and the change in serum NTproBNP (%) (_r_~S~=0.57, _p_=0.011). Eight (_n_=8; 89%) AL patients and seven (_n_=7, 70%) ATTR patients had a decrease in cardiac SUVR. Cardiac uptake of ^124^I-evuzamitide (_N_=19) correlated significantly with contemporaneous serum NTproBNP (_r_~P~=0.64, _p_=0.0034).
**Conclusion:**  ^124^I-evuzamitide uptake in the heart may be used to monitor changes in amyloid load (Fig. 1). These pilot data indicate that changes in radiotracer uptake correlate with changes in serum NTproBNP, a validated biomarker predictive of survival in AL amyloidosis.



Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers  OB1 (#296)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.